Table 2. Critical appraisal of included studies.
AMSTAR: A MeaSurement Tool to Assess systematic Reviews.
| Title | Author | Type of study | Quality assessment tool used | Quality score |
| The longer-term benefits and harms of glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis | Alexander et al. [17] | Systematic review and meta-analysis | AMSTAR | 91% |
| Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta‑analysis | D’Andrea et al. [18] | Systematic review and meta-analysis | AMSTAR | 100% |
| GLP‑1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta‑analysis of eight CVOTs | Giugliano et al. [19] | Meta-analysis | AMSTAR | 91% |
| The effect of DPP‑4 inhibitors, GLP‑1 receptor agonists and SGLT‑2 inhibitors on cardiorenal outcomes: a network meta‑analysis of 23 CVOTs | Giugliano et al. [20] | Meta-analysis | AMSTAR | 91% |
| Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis | Kanie et al. [21] | Meta-analysis | AMSTAR | 100% |
| Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis | Kelly et al. [22] | Systematic review and meta-analysis | AMSTAR | 82% |
| A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction | Liu et al. [23] | Meta-analysis | AMSTAR | 82% |
| Glucagon‑like peptide‑1 (GLP‑1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta‑analysis of double‑blind, randomized, placebo‑controlled clinical trials | Qin et al. [24] | Meta-analysis | AMSTAR | 100% |
| Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis | Sattar et al. [25] | Meta-analysis | AMSTAR | 82% |
| Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis | Wei et al. [26] | Systematic review and meta-analysis | AMSTAR | 91% |
| Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis | Wei et al. [27] | Meta-analysis | AMSTAR | 82% |
| Cardiovascular and renal outcomes with SGLT‑2 inhibitors versus GLP‑1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta‑analysis | Yamada et al. [28] | Systematic review and meta-analysis | AMSTAR | 91% |
| The potential of glucagon-like peptide-1 receptor agonists in heart failure | Kreiner et al. [29] | Narrative review | SANRA | 92% |
| GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes | Marx et al. [30] | Narrative review | SANRA | 92% |